To include your compound in the COVID-19 Resource Center, submit it here.
Elan began the double-blind, placebo-controlled, U.S. Phase II ELND005-BPD201 trial to evaluate oral ELND005 as an adjunctive
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury